

Figure 1. The relation between CH-C and the phenotype of autoimmune- diseases. The prevalence of these diseases in CH-C (n = 250) was significantly higher than in other chronic liver diseases (n = 98) (p = 0.0011) (A). The prevalence of these diseases and the positive rate of cryoglobulin, ANA (>40 times), ASMA (>20 times) and AMA (>20 times), and the amount of IgG (>2000mg/dl) are shown (B). doi:10.1371/journal.pone.0098521.g001

RNA, were used for the infection of several kinds of human primary lymphoid cells (1×10^5 cells). A control infection with UV-irradiated HCV was included in every experiment. The supernatant of Huh-7 cells transfected with JFH-1 strains at 10 days post-

transfection was used for several control experiments. The HCV-1T strain obtained from a CH-C patient without extrahepatic diseases and lymphoproliferative diseases was also used for several control experiments.




Figure 2. The cytokine conditions affecting the positivity of ANA and Cryoglobulin, and Th17 development. A comparison of the amounts of IL6 and TGF-β among the CH-C, CH-B, NASH and healthy subjects is shown (A). The bar indicates the mean cytokine amounts. The frequency of TGF-β1 high, IL6 high, and TGF-β1 and IL6 double high patients among the 4 groups (CH-C, CH-B, NASH, and healthy subjects) is shown (B). The positive rate of ANA and Cryoglobulin in the double high CH-C patients (n=9) and the other CH-C patients (n=26) is shown (C). The IL6 and TGF-β1 mRNA expression of PBMCs in the double-high patients (n=9) and other patients (n=26) is shown in the bar graphs (D). The amounts of IL1β, IL17A, IL21 and IL23 in the serum were compared between double high CH-C patients (n=9) and the other CH-C patients (n=26) (E). The comparisons of serum cytokines before and after the Peg-interferon/Ribavirin treatment are shown (F). Serum samples were collected at just before the treatment and twelve month after the end of treatment. SVR indicates sustained virological treatment (n=5). doi:10.1371/journal.pone.0098521.g002

The analysis of IL17-secreting CD4⁺ T cells

Naïve CD4⁺ cells were negatively isolated by using a naïve CD4⁺ T cells isolation kit II (Miltenyi Biotec). Isolated naïve CD4⁺ cells were exposed to SB-HCV, Ly-HCV, UV-irradiated-SB-HCV, UV-irradiated-Ly-HCV or Mock. Then, CD3⁺CD28⁺ coated beads and various kinds of cytokines were added to the culture medium to analyze the Th17 commitment and development (Table S1). The cytokine conditions for Th17 commitment and development included IL-1β (10 ng/ml), and IL23 (1 ng/ml), which are important for the Th17 development in human, because the differentiation of Th17 cells is very difficult without these cytokines when using human PBMCs[30]. The cells were harvested at 7 days post-inoculation and IL17A-secreting cells were analyzed by MACS cytokine secretion assay (Miltenyi Biotec).

Transwell co-culture system

The trans-membrane with 0.4 um pore size was used for the analysis of soluble factor-inducing Th17 cells, especially IL6 and TGF-β1. The upper chamber included PBMCs (2×10⁶ cells/ml) of CH-C patients (Ly-HCV or HCV-1T). The lower chamber included naïve CD4⁺ cells (2×10⁵ cells/ml) of a healthy individual and CD3CD28 coated beads with or without IL6 (40 ng/ml)(abcam) and TGF-β1 (40 ng/ml)(abcam) neutralizing antibodies. After five days incubation, the total RNA was isolated from cells of the lower chamber. The expression levels of RORγt were analyzed by real time PCR.

Construction of Lenti-virus expressing HCV-Core antigen

HCV core cDNA cloned in pcDNA3 was kindly provided by Dr. K. Takeuchi [31]. The full length HCV core cDNA was cloned into lentiviral vector, pCSII-EF plasmid, to create the pCSII-EF-HCV core[32]. The pCSII-EF-HCV core or control pCSII-EF-IRES-GFP plasmid was transfected into HEK293T cells together with two packaging plasmids, pCAG-HIVgp and pCMV-VSV-G/RSV-Rev (provided by the RIKEN Bio-resource Center), using the calcium phosphate method. The supernatants containing the recombinant lenti-virus were used for the infection of human primary lymphocyte.

Transfection of HCV individual protein expression plasmids

Various expression plasmids were constructed by inserting HCV-core, E1, E2, NS3, NS4B, NS5A and NS5B cDNA of genotype 1a behind the cytomegalovirus immediate-early promoter in pcDNA3.1 (Invitrogen). Primary CD4⁺ cells were transfected

Table 1. The frequency of Strand specific-HCV-RNA positive CD4+ T cells and CD19+ B cells.

	Negative-st-positive		Positive-st-positive	
	% (n: positive/total)		% (n: positive/total)	
	Double High (n = 9)	33.3 (3/9)		44.4 (4/9)
CD4+ T cell			p = 0.0166	p = 0.033
	Other (n = 26)	3.8 (1/26)		11.5 (3/26)
	Double High (n = 9)	44.4 (4/9)		66.6 (6/9)
CD19+ B cell			p = 0.0027	p = 0.0003
	Other (n = 26)	3.8 (1/26)		7.6 (2/26)

St-specific HCV-RNA were detected by nested PCR with rTth polymerase. Double high indicates that the amount of IL6 and TGF- β are high.
doi:10.1371/journal.pone.0098521.t001

ed using 4D-Nucleofector II (Amaxa, Gaithersburg, Washington DC, USA) with a human T cell nucleofector kit (Amaxa), and various plasmids were purified using the EndFree plasmid kit (QIAGEN, Valencia, CA, USA). Viable transfected cells were isolated by Ficoll-Paque centrifugation (Amersham Bioscience) at 24 hour post-transfection. The transfection and expression efficiencies were analyzed using intracellular staining of individual proteins of HCV and flow cytometry analysis.

Real-time PCR analysis

Cells were collected before the inoculation of lenti-virus and 10 days after the inoculation of lenti-virus. Total RNA was isolated using a column isolation kit (QIAGEN). After the isolation of RNA, one-step real-time PCR using a TaqMan Chemistry System was carried out. The ready-made set of primers and probe for the amplification of IL-6 (Hs00985639_m1), TGF- β 1 (Hs00998133_m1), T-bet (Hs00203436_m1), GATA-3 (Hs00231122_m1), RORC (Hs01076112_m1) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (Hs03929097_g1) were purchased from Applied Biosystems. The relative amount of target mRNA was obtained using a comparative threshold cycle (CT) method. The expression level of mRNAs of the non-stimulation sample of mock infected CD4⁺ cells was represented as 1.0 and the relative amounts of target mRNA were calculated according to the manufacturer's protocol.

The analysis of STAT-1 and STAT-3 signaling

STAT-1 and STAT-3 signaling was analyzed by phospho-STAT-1 (Tyr701) and phospho-STAT-3 (Tyr705) sandwich ELISA kit (Cell Signaling Technology). Briefly, naïve CD4⁺ cells transfected with or without HCV-core expressing plasmid were incubated with IL6 and TGF- β 1. The cells were harvested at various time points. Then, the cell lysates were used for the quantification of phospho-STAT-1 and phospho-STAT-3.

Statistical analysis

The data in Figure 1A, 1B, 2B and 2C were analyzed by χ^2 test. The data in Figure 2D and 2E were analyzed by independent Students t test. Figure 3A, 3C, 4A, 4B and 4C were analyzed by Mann-Whitney U test. All statistical analyses were carried out using JMP Pro version 9.

Accession Numbers

Accession number EntryID
AB779562 51027b2b6a8011fb860007e4.LyHCVserumSR
Accession number EntryID

AB779679 51029c6f6a8011fb8600093e.LyHCVpbmcSR

Results

Prevalence of autoimmune-related diseases in the CH-C patients

The prevalence of autoimmune-related disease in the CH-C patients was significantly higher than in the subjects with other chronic liver diseases in Tohoku University Hospital ($p = 0.0011$) (Fig.1A). In addition to the prevalence of autoimmune-related diseases, we analyzed the immunological laboratory tests including cryoglobulin, anti-nuclear antibody (ANA), anti-smooth muscle antibodies (ASMA), Immunoglobulin G (IgG), anti-mitochondrial antibody (AMA). The frequency of ANA positive or cryoglobulin positive patients in CH-C patients was significantly higher than in those with other chronic liver diseases ($p < 0.05$) (Fig.1B).

The amount of IL6 and TGF- β 1 in the peripheral blood of CH-C patients

The average amounts of IL6 and TGF- β 1 were comparable among healthy subjects, CH-C, CH-B and NASH (IL6: 1.77, 5.83, 4.84 and 5.99 pg/ml), (TGF- β : 1.45, 4.18, 4.68 and 4.5 mg/ml), (average amount) (Fig. 2A). However, the frequency of patients with high amounts of IL6 (over 8 pg/ml) and TGF- β 1 (over 5 ng/ml) (double-high) was significantly higher than in those with other chronic liver diseases ($p < 0.05$) (Fig. 2B). The cut-off levels of high amount of IL6 (over 8 pg/ml) and TGF- β 1 (over 5 ng/ml) were determined by the appearance of two clusters (high and low) in the CH-C samples. Interestingly, Most of the TGF- β 1 high CH-C patients had high amounts of IL6 (Fig. 2B). Moreover, the amount of IL6 were significantly correlated with the amount of TGF- β 1 (data not shown). The serum amounts of IL6 and TGF- β 1 were analyzed at 6 months after the sampling points. The serum amount of IL6 and TGF- β 1 in the high amount of IL6 and TGF- β 1 both (double-high) patients remained doubly high (data not shown). It has been reported that the combination of IL6 and TGF- β 1 cytokines could induce Th17 cells [20]. Therefore, we compared the frequency of ANA-positive or cryoglobulin-positive patients between double-high patients and the other patients with HCV persistent infection. The frequency of ANA-positive or cryoglobulin-positive patients among the double-high patients was significantly higher than among the other CH-C patients ($p < 0.01$) (Fig. 2C). The expression of IL-6 and TGF- β 1-mRNA in PBMCs of double-high patients was significantly higher than in other CH-C patients ($p < 0.05$) (Fig. 2D). Moreover, the serum amounts of IL1- β , IL17A, IL21 and IL23 in the double-high

Table 2. The frequency of different nucleotide bases between LyHCVserumSR and LyHCVpbmcSR.

Nucleo tide Position	LyHCVserumSR					LyHCVpbmcSR						
	Max base	No. of nucleotide	A (%)	C (%)	G (%)	T (%)	Max base	No. of nucleotide	A (%)	C (%)	G (%)	T (%)
538	G	1835	482 (26.27)	3 (0.16)	1349 (73.51)	1 (0.05)	A	1	1 (100.0)	0 (0.00)	0 (0.00)	0 (0.00)
659	G	1821	484 (26.58)	1 (0.05)	1334 (73.26)	2 (0.11)	A	1	1 (100.0)	0 (0.00)	0 (0.00)	0 (0.00)
1,026	A	2041	1098 (53.80)	2 (0.10)	939 (46.01)	2 (0.10)	G	3	1 (33.33)	0 (0.00)	2 (66.67)	0 (0.00)
1,034	C	2120	4 (0.19)	1263 (59.58)	0 (0.00)	853 (40.24)	T	3	0 (0.00)	1 (33.33)	0 (0.00)	2 (66.67)
1,280	C	2050	2 (0.10)	1785 (87.07)	2 (0.10)	261 (12.73)	T	7	0 (0.00)	2 (28.57)	0 (0.00)	5 (71.43)
2,050	C	1595	11 (0.69)	930 (58.31)	652 (40.88)	2 (0.13)	G	4	0 (0.00)	1 (25.00)	3 (75.00)	0 (0.00)
2,105	T	1852	1 (0.05)	587 (31.70)	0 (0.00)	1264 (68.25)	C	6	0 (0.00)	4 (66.67)	0 (0.00)	2 (33.33)
2,114	A	1814	1261 (69.51)	525 (28.94)	22 (1.21)	6 (0.33)	C	7	3 (42.86)	4 (57.14)	0 (0.00)	0 (0.00)
2,136	T	1813	0 (0.00)	527 (29.07)	1 (0.06)	1285 (70.88)	C	7	0 (0.00)	4 (57.14)	0 (0.00)	3 (42.86)
2,159	T	1904	0 (0.00)	505 (26.52)	1 (0.05)	1398 (73.42)	C	7	0 (0.00)	4 (57.14)	0 (0.00)	3 (42.86)
2,234	C	2023	5 (0.25)	1128 (55.76)	3 (0.15)	887 (43.85)	T	9	0 (0.00)	3 (33.33)	0 (0.00)	6 (66.67)
2,249	C	2030	5 (0.25)	1471 (72.46)	0 (0.00)	554 (27.29)	T	8	0 (0.00)	3 (37.50)	0 (0.00)	5 (62.50)
2,717	G	1841	471 (25.58)	1 (0.05)	1365 (74.14)	4 (0.22)	A	3	2 (66.67)	0 (0.00)	1 (33.33)	0 (0.00)
3,878	T	2449	3 (0.12)	37 (1.51)	1 (0.04)	2408 (98.33)	C	3	0 (0.00)	2 (66.67)	0 (0.00)	1 (33.33)
4,043	C	1894	14 (0.74)	1836 (96.94)	0 (0.00)	44 (2.32)	T	3	0 (0.00)	1 (33.33)	0 (0.00)	2 (66.67)
4,473	C	2105	811 (38.53)	1292 (61.38)	1 (0.05)	1 (0.05)	A	5	4 (80.00)	1 (20.00)	0 (0.00)	0 (0.00)
4,661	C	2263	2 (0.09)	1301 (57.49)	1 (0.04)	959 (42.38)	T	6	0 (0.00)	0 (0.00)	0 (0.00)	6 (100.0)
5,087	G	2050	477 (23.27)	1 (0.05)	1572 (76.68)	0 (0.00)	A	5	3 (60.00)	0 (0.00)	2 (40.00)	0 (0.00)
5,114	G	1791	32 (1.79)	452 (25.24)	1306 (72.92)	1 (0.06)	C	3	0 (0.00)	2 (66.67)	1 (33.33)	0 (0.00)
5,117	A	1674	1262 (75.39)	1 (0.06)	411 (24.55)	0 (0.00)	G	3	1 (33.33)	0 (0.00)	2 (66.67)	0 (0.00)
5,156	G	1871	481 (25.71)	0 (0.00)	1389 (74.24)	0 (0.00)	A	3	2 (66.67)	0 (0.00)	1 (33.33)	0 (0.00)
5,462	C	2026	2 (0.10)	1452 (71.67)	3 (0.15)	569 (28.08)	T	11	0 (0.00)	3 (27.27)	0 (0.00)	8 (72.73)
5,535	T	2059	1 (0.05)	490 (23.80)	0 (0.00)	1568 (76.15)	C	9	0 (0.00)	5 (55.56)	0 (0.00)	4 (44.44)
5,799	G	2113	477 (22.57)	0 (0.00)	1634 (77.33)	1 (0.05)	A	3	2 (66.67)	0 (0.00)	1 (33.33)	0 (0.00)
5,804	C	2131	3 (0.14)	1613 (75.69)	3 (0.14)	511 (23.98)	T	3	0 (0.00)	1 (33.33)	0 (0.00)	2 (66.67)
5,807	T	2102	2 (0.10)	490 (23.31)	5 (0.24)	1604 (76.31)	C	3	0 (0.00)	2 (66.67)	0 (0.00)	1 (33.33)
5,831	T	2168	7 (0.32)	483 (22.28)	5 (0.23)	1672 (77.12)	C	3	0 (0.00)	2 (66.67)	0 (0.00)	1 (33.33)
5,834	T	2153	2 (0.09)	504 (23.41)	0 (0.00)	1647 (76.50)	C	3	0 (0.00)	3 (100.0)	0 (0.00)	0 (0.00)
5,837	C	2144	3 (0.14)	1674 (78.08)	2 (0.09)	465 (21.69)	T	3	0 (0.00)	1 (33.33)	0 (0.00)	2 (66.67)
5,882	T	2160	0 (0.00)	480 (22.22)	0 (0.00)	1680 (77.78)	C	3	0 (0.00)	2 (66.67)	0 (0.00)	1 (33.33)
5,883	C	2114	0 (0.00)	1502 (71.05)	1 (0.05)	611 (28.90)	T	3	0 (0.00)	1 (33.33)	0 (0.00)	2 (66.67)
5,969	T	2238	2 (0.09)	80 (3.57)	1 (0.04)	2155 (96.29)	A	1	1 (100.00)	0 (0.00)	0 (0.00)	0 (0.00)
5,978	C	2451	1 (0.04)	2013 (82.13)	1 (0.04)	436 (17.79)	T	1	0 (0.00)	0 (0.00)	0 (0.00)	1 (100.0)

Table 2. Cont.

Nucleo tide Position	LyHCVserumSR						LyHCVpbmcSR					
	Max base	No. of nucleotide	A (%)	C (%)	G (%)	T (%)	Max base	No. of nucleotide	A (%)	C (%)	G (%)	T (%)
7,172	C	2409	2 (0.08)	1696 (70.40)	1 (0.04)	707 (29.35)	T	3	0 (0.00)	1 (33.33)	0 (0.00)	2 (66.67)
7,274	A	2654	1564 (58.93)	5 (0.19)	1074 (40.47)	11 (0.41)	G	7	3 (42.86)	0 (0.00)	4 (57.14)	0 (0.00)
7,349	G	2510	1019 (40.60)	5 (0.20)	1484 (59.12)	2 (0.08)	A	6	4 (66.67)	0 (0.00)	2 (33.33)	0 (0.00)
7,932	G	2810	1354 (48.19)	0 (0.00)	1453 (51.71)	3 (0.11)	A	9	7 (77.78)	0 (0.00)	2 (22.22)	0 (0.00)
8,093	G	2647	684 (25.84)	3 (0.11)	1956 (73.89)	4 (0.15)	A	7	4 (57.14)	0 (0.00)	3 (42.86)	0 (0.00)
8,168	G	1993	39 (1.96)	1 (0.05)	1952 (97.94)	1 (0.05)	A	2	1 (50.00)	0 (0.00)	1 (50.00)	0 (0.00)
8,237	C	2077	1 (0.05)	2033 (97.88)	0 (0.00)	42 (2.02)	T	3	0 (0.00)	1 (33.33)	0 (0.00)	2 (66.67)
8,672	G	2340	17 (0.73)	576 (24.62)	1734 (74.10)	12 (0.51)	C	3	0 (0.00)	2 (66.67)	1 (33.33)	0 (0.00)
8,693	T	2899	5 (0.17)	690 (23.80)	0 (0.00)	2204 (76.03)	C	3	0 (0.00)	2 (66.67)	0 (0.00)	1 (33.33)

doi:10.1371/journal.pone.0098521.t002

Table 3. Detection of St-Specific HCV-RNA in various kinds of lymphoid cell.

Immune cells	Raji				mir122Raji				Molt-4				naive T (IL-2)				naive T (IL6)				naive T (TGF-β)				naiveT (IL6 and TGF-β)					
	JFH	HCV	SB	Ly	JFH	HCV	SB	Ly	JFH	HCV	SB	Ly	JFH	HCV	SB	Ly	JFH	HCV	SB	Ly	JFH	HCV	SB	Ly	JFH	HCV	SB	Ly		
Positive Strand																														
2 days	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
7 days	0	1	16	4	0	1	64	16	0	1	16	4	0	0	16	4	0	0	4	4	0	0	16	4	0	0	16	4	0	4
7 days-UV-irradiated	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Negative Strand																														
2 days	0	0	1	0	0	0	1	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
7days	0	0	4	1	0	0	16	4	0	0	4	1	0	0	4	1	0	0	1	1	0	0	4	1	0	0	4	1	0	4
7days-UV-irradiated	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

The titers of HCV-RNA were expressed as the highest dilution giving a visible band of the correct size. Naïve T cells were incubated with IL-1β (10 ng/ml), IL23 (1 ng/ml), and CD3CD28 coated beads. JFH-1 and HCV-1T are not lymphotropic HCV strains. SB-HCV and Ly-HCV are lymphotropic HCV strains. mir122Raji indicate miR122-transduced RIG-1/MDA-knockdown Raji. doi:10.1371/journal.pone.0098521.t003




Figure 3. The effect of lymphotropic HCV on the Th17 development in various kinds of cytokines condition. Isolated naïve CD4⁺ cells were exposed to SB-HCV, Ly-HCV, UV-irradiated-SB-HCV, Ly-HCV or Mock. Then, CD3⁺CD28⁺ coated beads and various kinds of cytokines were added to the culture medium to analyze the Th17 commitment and development (Suppl. Table 1). The cells were harvested at 7 days post-inoculation and IL17A-secreting cells were analyzed by MACS cytokine secretion assay. The frequencies of CD4⁺

IL17A⁺ cells among the CD4⁺ cells were shown in the bar graph (A). The bar graph indicates the frequencies of Th17 cells with or without lymphotropic HCV in the various kinds of cytokine conditions (A). The schema of the transwell system is shown (B). The expression of ROR γ t mRNA in naïve T lymphocytes with or without various kinds of stimulations is shown (C). The obtained data were analyzed by Mann-Whitney U test. Three independent experiments were carried out (A)(C). doi:10.1371/journal.pone.0098521.g003

patients were significantly higher than in the other CH-C patients ($p < 0.01$) (Fig. 2E). Moreover, these cytokines were significantly correlated with the amount of IL6 and TGF- β 1 (data not shown). Then, we quantified the serum cytokines at the twelve months after the Peg-interferon/Ribavirin-treatment among double high patients. The serum amounts of IL-1 β , IL17A, IL21 and IL23 were significantly decreased after the achievement of the sustained virological response (SVR) (Fig. 2F).

The relation between lymphotropic HCV and patients with high amounts of IL6 and TGF- β 1 (Double-High)

Previously, Machida et al. described that HCV replication in B lymphocytes could induce their secretion of IL6. Therefore, we analyzed the relationship between lymphotropic HCV and patients with double-high by detecting strand-specific HCV-RNA in the CD4⁺ T cells and CD19⁺ B cells. The frequency of positive and negative-strand-specific-HCV-RNA in double-high CH-C patients was significantly higher than in the other CH-C patients (Table 1). These data indicated that the lymphotropism of HCV could be related to the IL6 and TGF- β 1 double-high environment.

Detection of a new lymphotropic HCV from a patient with lympho-proliferative disease

Previously, we used a lymphotropic SB-HCV that was reported by Sung et al[29]. In this study, we found a patient who had higher amounts of HCV RNA in the lymphocytes in comparison to other CH-C patients. This lymphotropic HCV (named Ly-HCV) is genotype 1b. The full-length sequence of this strain was analyzed by deep sequencing of both serum and PBMC samples. Phylogenetic tree analysis was then carried out (Fig. S1A). To characterize the metagenomics of HCV infection in human serum, LyHCVserumSR (registered in DDBJ; the accession number, AB779562) and PBMC, LyHCVpbmcSR (registered in DDBJ; the accession number, AB779679), we analyzed the samples by paired end deep sequencing. The coverage was 100.0% and the average depth was 2092.1 \times (Fig. S1B).

The LyHCVserumSR and LyHCVpbmcSR isolates were 99.5% identical to each other within the overlapping region. In 42 nucleotide bases, the major nucleotide bases showed differences. However, only the proportions of nucleotide sequences were different (Table 2). The sequences of HCV-RNA obtained from serum and PBMCs were almost the same (Table 2). Therefore, we used the diluted Ly-HCV-serum for the *in vitro* infection study.

Analysis of Infectivity of Ly-HCV and SB-HCV under the various kinds of cytokines

We examined the infectivity of Ly-HCV and SB-HCV into several lymphoid-cell lines (Raji, miR122-transduced RIG-1/MDA-knockdown Raji, and Molt-4) and primary naïve CD4⁺ T cells. Semi-quantitative strand-specific nested PCR was carried out as in our previous reports (Table 3). The infectivity of HCV in the IL-6 and TGF- β cytokine combination conditions with low dose IL1 β , IL23 and CD3CD28 coated beads was no better than that






Figure 4. The identification of proteins responsible for enhancing the Th17 development (A). The transfection of various kinds of plasmids expressing HCV-individual proteins (E1, E2, Core, NS3, NS4B, NS5A, NS5B and vector) was carried out by nucleofector. The cells were analyzed at 72 hours post-transfection. The bar graph indicates the IL17A-secreting cells among the sample's CD4⁺ cells/IL17A secreting cells and the vector's CD4⁺ cells × 100. The obtained data were analyzed by Mann-Whitney U test. Three independent experiments were carried out. **The analysis of STAT-1 and STAT-3 signaling (B).** We used a pathscan to quantify sequentially the phosphor-STAT-1 and STAT-3. The dotted lines indicate data of the vector control. Three independent experiments were carried out. **Long-term culture affected the commitment of naïve T lymphocytes with HCV-core expressing Lenti-virus (C).** The gene expressions of T-bet, GATA-3 and ROR γ t were analyzed by real-time PCR. The relative amounts of mRNA were calculated by $\Delta\Delta$ CT methods. The target gene expressions were analyzed at pre-inoculation of Lent-virus and 10 days after the inoculation of lenti-virus. Three independent experiments were carried out. doi:10.1371/journal.pone.0098521.g004



in IL2, IL6, or TGF- β cytokine only conditions with low dose IL1 β , IL23 and CD3CD28 coated beads.

The effect of lymphotropic HCV on the Th17 development

The addition of both IL6 and TGF- β 1 could significantly induce IL17-secreting T cells (Th17) in comparison to IL6 or TGF- β 1 alone (Fig 3A). Both lymphotropic HCV strains (SB-HCV and Ly-HCV) could significantly up-regulate the Th17 development in comparison to Mock and these strains that had been UV-irradiated. Then, we used a co-culture system to analyze the blocking of IL6 and TGF- β 1 effects since the expressions of IL6 and TGF- β 1 mRNA in PBMCs of double high patients were significantly higher than those in other CH-C patients (Fig. 2D and Fig. 3B). The IL-6 was produced from B lymphocytes. Moreover, the major TGF- β 1 producing cells were monocytes in double high patients (Data not shown). The soluble factors produced from PBMCs of Ly-HCV-patient could significantly induce Th17 master gene ROR γ t in comparison to mock and PBMCs of HCV-1T patient (Fig. 3C). The addition of IL6 and TGF- β 1 neutralizing antibody significantly reduced the expression of ROR γ t, especially IL6 neutralizing antibody (Fig. 3C).



The identification of HCV proteins and signal transduction responsible for the production of IL17A

We used E1, E2, Core, NS3, NS4B, NS5A and NS5B expressing plasmids to transiently express these proteins in naïve T cells. The transfection efficiencies were 45.4 ± 4.96% (average ± standard deviation). Among these proteins, only HCV-Core protein could significantly enhance the production of IL17A cells (Fig. 4A)(p<0.05). In addition to in vitro circumstance, we used NOD/scid/ γ c^{null} (NOG) mice that are super-immunodeficiency mice[33]. The transfusions of HCV-core expressing human primary lymphoid cells were carried out (*ongoing Kondo Y et al.*). The higher amount of IL17A and ROR γ t mRNA were detected in the HCV-Core expressing CD4⁺ cells in comparison to the control groups (data not shown). Then, we sequentially analyzed the STAT-1 and STAT-3 activation by IL6 and TGF- β 1 stimulation in the HCV-Core expressing T cells. The results indicated that STAT-3 signaling was significantly enhanced in comparison to mock-transfected T cells (Fig. 4B)(p<0.05). These data indicated that HCV-Core protein enhanced the STAT-3 signaling following the induction of the Th17 master gene-ROR γ t.

Long-term culture of primary naïve T lymphocytes with HCV-core expressing lenti-virus

We constructed the HCV-core expressing lenti-virus to analyze the long-term culture of primary naïve T lymphocytes with the expression of HCV core protein. The efficiency of lenti-virus infection was $27.7 \pm 3\%$ (average \pm standard deviation). In addition to IL1 β and IL23, the IL6 and TGF- β 1 cytokine conditions could remarkably induce the ROR γ t mRNA (Fig.4C). Moreover, significantly higher amounts of ROR γ t mRNA were detected in the HCV-core expressing T lymphocytes in comparison with the control groups (Fig. 4C)($p < 0.05$).

Discussion

Autoimmune thyroiditis, systemic lupus erythematosus, idiopathic thrombocytopenic purpura, autoimmune hepatitis and rheumatoid arthritis etc. could be classified not only as HCV-related diseases but also as Th17-related autoimmune diseases [16–19,34–36]. In this study, we clearly demonstrated the relevance of lymphotropic HCV to autoimmune-related diseases including an important role of Th17 cells in CH-C patients. This study revealed two important mechanisms by which Th17 development is enhanced. In the first, the existence of lymphotropic HCV can result in the IL6 and TGF- β 1 double high condition that can enhance Th17 development. Previously, Machida et al. described that HCV replication in B cells induced IL6 production from B cells [24]. In the second, the existence of HCV in naïve T cells can enhance Th17 development in the IL6 and TGF- β 1 double high condition by enhancing STAT-3/ROR γ t signaling. Previously, we showed that lymphotropic HCV could suppress IFN- γ /STAT-1/T-bet signaling, which could contribute to the persistence of hepatitis C virus infection [1,4,13]. STAT-3 signaling could be enhanced by the suppression of STAT-1 signaling. However, the finding of our research was surprising. Therefore, we examined this phenomenon studiously and carefully. First, we found a novel genotype, 1b lymphotropic HCV strain (Ly-HCV), that could infect Raji and human primary lymphocytes. Although the infectivity of this strain was lower than that of SB-HCV [29], we could detect negative and positive strand RNA in naïve T lymphocytes with stimulation.

Therefore, we used two lymphotropic HCV strains to analyze the effect on Th17 development. Moreover, two kinds of expression experiments showed that HCV-Core could enhance the STAT-3/ROR γ t signaling, since the method of gene expression and the period of incubation might affect the result of T cell development. However, the results of our two kinds of experiments (plasmids and lenti-virus) consistently showed that the expression of HCV-core protein in T lymphocytes could enhance the Th17 development. Other groups previously reported that HCV-core protein could affect anergy-related genes and T cell responses by inducing spontaneous and alternating T-cell receptor-triggered Ca²⁺ oscillations [37,38]. Therefore, the expression of HCV-core protein in T lymphocyte might be important for the

functional changes in T lymphocytes. Although our study confirmed that the replication of HCV in lymphocytes is important, there was a bystander effect by exosome produced from HCV-infected lymphocytes. Previously, our group reported that exosome could transport miRNA and proteins in the microenvironment [39,40]. This phenomenon could explain the significant effects of a low level of HCV infection in lymphocytes. Moreover, the naïve T lymphocyte is located upstream of Th17 development. Therefore, we should not underestimate the effect of a low-level of HCV replication in lymphocytes.

In conclusion, we report the detailed mechanism of Th17 development and HCV infection, which might be involved in the pathogenesis of autoimmune-related disease in CH-C patients (Fig S2). Recently, a novel therapy targeting STAT-3 signaling was reported [23,41,42]. We should consider the clinical use of such treatments for autoimmune-related diseases in CH-C patients.

Supporting Information

Figure S1 Phylogenetic trees constructed based on the nearly entire nucleotide sequence of HCV by using the unweighted pair group method with the arithmetic mean (Michener 1957). The tree includes the three genotype 1a isolates, forty 1b, one 1c, three 2a, two 2b, one 2c and one 3a, 3b, 6b, 7b, 9b, 10a, whose nucleotide sequence data were retrievable from the GenBank/EMBL/DDBJ database (A). Mapping to the consensus HCV genome sequence. For Ly-HCV 0183-4, 197,414 reads were mapped (Fig S1B). The coverage was 100.0%, and the average depth was 2092.1x. For Ly-HCV 0186-1, 410 reads were aligned. The coverage was 95.9%, and the average depth was $4.3 \times$ (B). (TIFF)

Figure S2 The schema of Th17 induction in perihepatic lymph node of CH-C patient with lymphotropic HCV are shown. (TIFF)

Table S1 Various kinds of cytokines conditions for in vitro analysis are shown in Table S1. (DOC)

Acknowledgments

We are grateful to Prof. Ishii N who gave us valuable insight regarding NOG mice. We thank M. Tsuda, N. Koshita, M. Kikuchi and K. Kuroda for technical assistance. We also acknowledge the technical support of the Biomedical Research Core of Tohoku University Graduate School of Medicine.

Author Contributions

Conceived and designed the experiments: YK MN OK TK ML TS. Performed the experiments: YK MN OK KM RF TN KK EK KN. Analyzed the data: YK MN OK TN KN ML TS. Contributed reagents/materials/analysis tools: KM. Wrote the paper: YK MN TN ML TS.

References

- Kondo Y, Ueno Y, Shimosegawa T (2012) Biological significance of HCV in various kinds of lymphoid cells. *International journal of microbiology* 2012: 647581.
- Kondo Y, Ueno Y, Wakui Y, Ninomiya M, Kakazu E, et al. (2011) Rapid reduction of hepatitis C virus-Core protein in the peripheral blood improve the immunological response in chronic hepatitis C patients. *Hepatology Res*.
- Kondo Y, Machida K, Liu HM, Ueno Y, Kobayashi K, et al. (2009) Hepatitis C virus infection of T cells inhibits proliferation and enhances fas-mediated apoptosis by down-regulating the expression of CD44 splicing variant 6. *J Infect Dis* 199: 726–736.
- Kondo Y, Sung VM, Machida K, Liu M, Lai MM (2007) Hepatitis C virus infects T cells and affects interferon-gamma signaling in T cell lines. *Virology* 361: 161–173.
- Machida K, Kondo Y, Huang JY, Chen YC, Cheng KT, et al. (2008) Hepatitis C virus (HCV)-induced immunoglobulin hypermutation reduces the affinity and neutralizing activities of antibodies against HCV envelope protein. *J Virol* 82: 6711–6720.
- Simula MP, Caggiari L, Gloghini A, De Re V (2007) HCV-related immunocytoma and type II mixed cryoglobulinemia-associated autoantigens. *Ann N Y Acad Sci* 1110: 121–130.

7. Ito M, Masumi A, Mochida K, Kukihara H, Moriishi K, et al. (2010) Peripheral B cells may serve as a reservoir for persistent hepatitis C virus infection. *J Innate Immun* 2: 607–617.
8. Pal S, Sullivan DG, Kim S, Lai KK, Kac J, et al. (2006) Productive replication of hepatitis C virus in perihepatic lymph nodes in vivo: implications of HCV lymphotropism. *Gastroenterology* 130: 1107–1116.
9. Karavattathayil SJ, Kalkeri G, Liu HJ, Gaglio P, Garry RF, et al. (2000) Detection of hepatitis C virus RNA sequences in B-cell non-Hodgkin lymphoma. *Am J Clin Pathol* 113: 391–398.
10. Ferri C, Zignego AL (2000) Relation between infection and autoimmunity in mixed cryoglobulinemia. *Curr Opin Rheumatol* 12: 53–60.
11. Mariette X (1999) Lymphomas in patients with Sjogren's syndrome: review of the literature and pathophysiologic hypothesis. *Leuk Lymphoma* 33: 93–99.
12. Mizukawa Y, Shiohara T (2000) Virus-induced immune dysregulation as a triggering factor for the development of drug rashes and autoimmune diseases: with emphasis on EB virus, human herpesvirus 6 and hepatitis C virus. *J Dermatol Sci* 22: 169–180.
13. Kondo Y, Ueno Y, Kakazu E, Kobayashi K, Shiina M, et al. (2011) Lymphotropic HCV strain can infect human primary naive CD4+ cells and affect their proliferation and IFN-gamma secretion activity. *J Gastroenterol* 46: 232–241.
14. MacParland SA, Pham TN, Gujar SA, Michalak TI (2006) De novo infection and propagation of wild-type Hepatitis C virus in human T lymphocytes in vitro. *J Gen Virol* 87: 3577–3586.
15. Hu Y, Shahidi A, Park S, Guilfoyle D, Hirshfield I (2003) Detection of extrahepatic hepatitis C virus replication by a novel, highly sensitive, single-tube nested polymerase chain reaction. *Am J Clin Pathol* 119: 95–100.
16. Bassiouny DA, Shaker O (2011) Role of interleukin-17 in the pathogenesis of vitiligo. *Clinical and experimental dermatology* 36: 292–297.
17. Horie I, Abiru N, Saitoh O, Ichikawa T, Iwakura Y, et al. (2011) Distinct role of T helper Type 17 immune response for Graves' hyperthyroidism in mice with different genetic backgrounds. *Autoimmunity* 44: 159–165.
18. Horie I, Abiru N, Sakamoto H, Iwakura Y, Nagayama Y (2011) Induction of autoimmune thyroiditis by depletion of CD4+CD25+ regulatory T cells in thyroiditis-resistant IL-17, but not interferon-gamma receptor, knockout nonobese diabetic-H2h4 mice. *Endocrinology* 152: 4448–4454.
19. Zhao L, Tang Y, You Z, Wang Q, Liang S, et al. (2011) Interleukin-17 contributes to the pathogenesis of autoimmune hepatitis through inducing hepatic interleukin-6 expression. *PLoS One* 6: e18909.
20. Ivanov, II, McKenzie BS, Zhou L, Tadokoro CE, Lepelley A, et al. (2006) The orphan nuclear receptor ROR γ directs the differentiation program of proinflammatory IL-17+ T helper cells. *Cell* 126: 1121–1133.
21. Harris TJ, Grosso JF, Yen HR, Xin H, Kortylewski M, et al. (2007) Cutting edge: An in vivo requirement for STAT3 signaling in TH17 development and TH17-dependent autoimmunity. *Journal of immunology* 179: 4313–4317.
22. Seddighzadeh M, Gonzalez A, Ding B, Ferreiro-Iglesias A, Gomez-Reino JJ, et al. (2012) Variants Within STAT Genes Reveal Association with Anticitrullinated Protein Antibody-negative Rheumatoid Arthritis in 2 European Populations. *The Journal of rheumatology* 39: 1509–1516.
23. Yu CR, Lee YS, Mahdi RM, Surendran N, Egwuagu CE (2012) Therapeutic targeting of STAT3 (signal transducers and activators of transcription 3) pathway inhibits experimental autoimmune uveitis. *PLoS One* 7: e29742.
24. Machida K, Cheng KT, Sung VM, Levine AM, Fong S, et al. (2006) Hepatitis C virus induces toll-like receptor 4 expression, leading to enhanced production of beta interferon and interleukin-6. *J Virol* 80: 866–874.
25. Korn T, Bettelli E, Oukka M, Kuchroo VK (2009) IL-17 and Th17 Cells. *Annual review of immunology* 27: 485–517.
26. Kondo Y, Iwata T, Haga T, Kimura O, Ninomiya M, et al. (2013) Eradication of hepatitis C virus could improve immunological status and pyoderma gangrenosum-like lesions. *Hepatology research: the official journal of the Japan Society of Hepatology*.
27. Negro F, Krawczynski K, Quadri R, Rubbia-Brandt L, Mondelli M, et al. (1999) Detection of genomic- and minus-strand of hepatitis C virus RNA in the liver of chronic hepatitis C patients by strand-specific semiquantitative reverse-transcriptase polymerase chain reaction. *Hepatology* 29: 536–542.
28. Hu Y, Shahidi A, Park S, Guilfoyle D, Hirshfield I (2003) Detection of extrahepatic hepatitis C virus replication by a novel, highly sensitive, single-tube nested polymerase chain reaction. *American journal of clinical pathology* 119: 95–100.
29. Sung VM, Shimodaira S, Doughty AL, Picchio GR, Can H, et al. (2003) Establishment of B-cell lymphoma cell lines persistently infected with hepatitis C virus in vivo and in vitro: the apoptotic effects of virus infection. *J Virol* 77: 2134–2146.
30. Tuomela S, Salo V, Tripathi SK, Chen Z, Laurila K, et al. (2012) Identification of early gene expression changes during human Th17 cell differentiation. *Blood* 119: e151–160.
31. Takeuchi K, Kubo Y, Boonmar S, Watanabe Y, Katayama T, et al. (1990) Nucleotide sequence of core and envelope genes of the hepatitis C virus genome derived directly from human healthy carriers. *Nucleic acids research* 18: 4626.
32. Zhou J, Yu Z, Zhao S, Hu L, Zheng J, et al. (2009) Lentivirus-based DsRed-2-transfected pancreatic cancer cells for deep in vivo imaging of metastatic disease. *The Journal of surgical research* 157: 63–70.
33. Shiokawa M, Takahashi T, Murakami A, Kita S, Ito M, et al. (2010) In vivo assay of human NK-dependent ADCC using NOD/SCID/gammac(null) (NOG) mice. *Biochemical and biophysical research communications* 399: 733–737.
34. Chen XQ, Yu YC, Deng HH, Sun JZ, Dai Z, et al. (2010) Plasma IL-17A is increased in new-onset SLE patients and associated with disease activity. *J Clin Immunol* 30: 221–225.
35. Pan HF, Leng RX, Feng CC, Li XP, Chen GM, et al. (2012) Expression profiles of Th17 pathway related genes in human systemic lupus erythematosus. *Mol Biol Rep*.
36. Hu Y, Li H, Zhang L, Shan B, Xu X, et al. (2012) Elevated profiles of Th22 cells and correlations with Th17 cells in patients with immune thrombocytopenia. *Hum Immunol* 73: 629–635.
37. Bergqvist A, Sundstrom S, Dimberg LY, Gylfe E, Masucci MG (2003) The hepatitis C virus core protein modulates T cell responses by inducing spontaneous and altering T-cell receptor-triggered Ca²⁺ oscillations. *J Biol Chem* 278: 18877–18883.
38. Dominguez-Villar M, Munoz-Suano A, Anaya-Baz B, Aguilar S, Novalbos JP, et al. (2007) Hepatitis C virus core protein up-regulates anergy-related genes and a new set of genes, which affects T cell homeostasis. *J Leukoc Biol* 82: 1301–1310.
39. Kogure T, Lin WL, Yan IK, Braconi C, Patel T (2011) Intercellular nanovesicle-mediated microRNA transfer: a mechanism of environmental modulation of hepatocellular cancer cell growth. *Hepatology* 54: 1237–1248.
40. Tamai K, Shiina M, Tanaka N, Nakano T, Yamamoto A, et al. (2012) Regulation of hepatitis C virus secretion by the Hrs-dependent exosomal pathway. *Virology* 422: 377–385.
41. Stump KL, Lu LD, Dobrzanski P, Serdikoff C, Gingrich DE, et al. (2011) A highly selective, orally active inhibitor of Janus kinase 2, CEP-33779, ablates disease in two mouse models of rheumatoid arthritis. *Arthritis research & therapy* 13: R68.
42. Zhang X, Yue P, Page BD, Li T, Zhao W, et al. (2012) Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts. *Proc Natl Acad Sci U S A* 109: 9623–9628.

Short Communication

Eradication of hepatitis C virus could improve immunological status and pyoderma gangrenosum-like lesions

Yasuteru Kondo,¹ Tomoaki Iwata,¹ Takahiro Haga,² Osamu Kimura,¹ Masashi Ninomiya,¹ Eiji Kakazu,¹ Takayuki Kogure,¹ Tatsuki Morosawa,¹ Setsuya Aiba² and Tooru Shimosegawa¹

Divisions of ¹Gastroenterology and ²Dermatology, Tohoku University Hospital, Sendai, Japan

Hepatitis C virus (HCV) can affect immune cells and induce various kinds of immune-related diseases including pyoderma gangrenosum. We experienced a difficult-to-treat case of pyoderma gangrenosum-like lesions in a patient with HCV infection. The patient was treated with pegylated interferon (PEG IFN)- α -2b and ribavirin (RBV) therapy and achieved a sustained virological response. Before the eradication of HCV, the frequency of T-helper 17 cells was remarkably high in comparison to chronic hepatitis C patients without extrahepatic immune-related diseases. Moreover, we could detect negative and positive strand-specific HCV RNA in the CD19⁺ B

lymphocytes and CD4⁺ T lymphocytes. However, after the eradication of HCV, the immunological status became normal and the pyoderma gangrenosum-like lesions became stable without immunosuppressive therapy. Here, we report a sequential immunological analysis during PEG IFN/RBV therapy and the beneficial effect of HCV eradication in difficult-to-treat pyoderma gangrenosum-like lesions.

Key words: CD19, CD4, extrahepatic diseases, hepatitis C virus, T-helper 17

INTRODUCTION

HEPATITIS C VIRUS (HCV) is non-cytopathic virus that causes chronic hepatitis C (CHC), and hepatocellular carcinoma (HCC), a lymphoproliferative disease. Approximately 70% of those acutely infected will develop CHC.¹ Various kinds of immune cells, including CD4⁺ T-helper (Th) cells, CD8⁺ cytotoxic T lymphocytes (CTL), B cells, regulatory T cells (Treg) and monocytes, may be affected by persistent infection of HCV.^{2–5} HCV can cause not only immunosuppression, which contributes to persistent infection, but also unfavorable immune activation, which can induce various kinds of extrahepatic manifestations, including immune-related diseases.^{3,4,6,7}

The extrahepatic manifestations of CHC include mixed cryoglobulinemia that represents a prototype of HCV-associated disorders.^{8–10} Mixed cryoglobulinemia is caused by various kinds of stimulation. It was reported that chronic antigenic stimulation may induce specific B-cell clones that could produce cryoglobulins. Moreover, B-cell activation and/or dysregulation could originate as a result of HCV binding to CD81 tetraspanin molecules or as a consequence of its ability to replicate in B lymphocytes.¹⁰ A variety of skin disorders are associated with an increased level of monoclonal immunoglobulin proteins. These kinds of disorders include pyoderma gangrenosum, leukocytoclastic vasculitis pemphigus, bullous pemphigoid, epidermolysis bullosa acquisita, Sézary syndrome, lymphomatoid papulosis, urticaria pigmentosa and acquired ichthyosis.¹¹ We experienced a CHC patient with severe pyoderma gangrenosum-like lesions treated with immunosuppressive therapy. However, the activity of the pyoderma gangrenosum-like lesions was not improved during immunosuppressive therapy. Then, we tried eradication of HCV by using pegylated interferon (PEG IFN) and ribavirin (RBV) therapy because a relationship between

Correspondence: Dr Yasuteru Kondo, Division of Gastroenterology, Tohoku University Hospital, 1-1 Seiryomachi, Aoba-ku, Sendai City, Miyagi 980-8574, Japan. Email: yasuteru@ebony.plala.or.jp

Conflict of interest: The authors declare that they have no conflict of interest.

Received 15 January 2013; revision 12 February 2013; accepted 21 February 2013.